Monitor upcoming Q2 2026 10-Q for actual revenue dollar figures and cash burn rate. The expansion to 12 US territories and international entry (starting with Israel) by year-end 2026 are key catalysts to watch. The Lovell government contract opens a federal channel but contribution timeline is uncertain.
Price Chart
Executive Summary
Microbot Medical reported greater than 100% sequential revenue and customer growth for Q2 2026 vs Q1 2026, driven by the full market launch of its LIBERTY Endovascular Robotic System. The company also expanded sales territories, secured an Israeli regulatory clearance, and established a second manufacturing site. While the growth rate is impressive, the absolute revenue base remains undisclosed and the company is still in early commercialization, making this a notable but not transformative update.
Key Facts
- Revenue and new customers grew >100% in Q2 2026 vs Q1 2026
- Full Market Release of LIBERTY System commenced April 13, 2026
- Sales territories expanded from 4 to 8 in Q2, targeting 12 by year-end
- Received marketing clearance from Israeli Ministry of Health (first non-US approval)
- Entered agreement with Lovell Government Services for federal healthcare systems (VHA, MHS, IHS)
- Established second manufacturing site to meet demand
- Existing LMR sites increased procedure volume in Q2 via site expansion and user migration
Financial Impact
Greater than 100% sequential revenue growth (absolute dollar amounts not disclosed)
Risk Factors
- Absolute revenue base is undisclosed — >100% growth from a very small base is less meaningful
- Commercial-stage company with limited operating history for the LIBERTY system
- Geopolitical risks from Israel operations (hostilities mentioned in risk factors)
- No profitability timeline provided; cash burn and dilution risk remain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-032260 |
| Exhibit: ex99-1.htm | 0001493152-26-032260 |
| Document: 0001493152-26-032260-index-headers.html | 0001493152-26-032260 |
| Document: 0001493152-26-032260-index.html | 0001493152-26-032260 |
| Document: 0001493152-26-032260.txt | 0001493152-26-032260 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $0.9739 $0.9417 | ▼ −3.31% | ▼ −4.02% | $0.9400 (−3.48%) |
Oct 20, 2026 6d ago | 8-K | $0.9475 $0.9401 | ▼ −0.78% | ▼ −1.31% | $0.9400 (−0.79%) |
Oct 6, 2026 20d ago | 8-K | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $0.9400 (−12.15%) |
Oct 6, 2026 20d ago | Press Release | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $0.9400 (−12.15%) |
Sep 28, 2026 28d ago | 8-K | $1.25 $1.25 | ▼ −0.40% | ▼ −0.22% | $0.9400 (−24.80%) |
Aug 11, 2026 10w ago | 8-K | $1.68 $1.74 | ▲ +3.27% | ▲ +3.02% | $0.9400 (−44.05%) |
Jul 21, 2026 13w ago | 8-K | $1.80 $1.77 | ▼ −1.67% | ▼ −1.55% | $0.9400 (−47.78%) |
Jul 7, 2026 15w ago | 8-K | $1.90 $1.87 | ▼ −1.58% | ▼ −1.27% | $0.9400 (−50.53%) |
Jun 30, 2026 16w ago | 8-K | $1.95 $1.91 | ▼ −2.05% | ▼ −1.92% | $0.9400 (−51.79%) |
Jun 16, 2026 18w ago | 8-K | $1.82 $1.88 | ▲ +3.30% | ▲ +4.55% | $0.9400 (−48.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers